Production and process controls, organization and personnel were the top problems found, while packaging and labeling citations increased in 2017 and 2018.
Naheed Sayeed
Advertisement
Articles by Naheed Sayeed
Advertisement
Latest Updated Articles
- Lessons from FDA 483s and cGMP Inspection Data
December 15th 2019
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
3
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
4
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
5